SER
AMEXSerina Therapeutics Inc.
Serina Therapeutics Inc. (SER) is a Biotechnology: Pharmaceutical Preparations company listed on AMEX. In the last 30 days Quantisnow tracked 1 wire item for SER, including 1 13D/G filing. The most recent was published Nov 3, 2026.
Financial highlights
Full financials- Revenue, TTM
- $0
- Net income, TTM
- -$21.18M
- Free cash flow, TTM
- -$21.20M
- Cash
- $23.02M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks39-50%
2026-05-172026-11-08
Mix1290d
- SEC Filings7(58%)
- Other3(25%)
- Leadership1(8%)
- 13D/G1(8%)
Activity · 52 weeks9458 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Serina Therapeutics Inc.SCHEDULE 13G/A - Serina Therapeutics, Inc. (0001708599) (Subject)
- SECSEC Form 8-K filed by Serina Therapeutics Inc.8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRRegistration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson’s disease with no major clinical advances in 50+ yearsMeet with Serina’s CEO Steven LedgerRegister at AdvancingParkinsonsDisease.TribePublic.com HUNTSVILLE, AL, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, is pleased to announce that Serina’s CEO, Steven Ledger will present at Tribe Public’s Webinar Presentation and Q&A Event titled "A N
- PRSerina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceHUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, today announced that Steve Ledger, Chief Executive Officer, will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The Company will also attend one-on-one investor meetings during the conference taking place September 14-16, 2026 in New York, New York. The presentation will be available for on-demand viewing starting on Monday, September 14, 2026, at
- PRSerina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of improvement in motor function in individual patients on exploratory clinical measures – - Serina expects to report topline data from the single-ascending-dose portion of the study in the first half of 2027 - HUNTSVILLE, Ala., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinic
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form EFFECT filed by Serina Therapeutics Inc.EFFECT - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form S-1 filed by Serina Therapeutics Inc.S-1 - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form S-8 filed by Serina Therapeutics Inc.S-8 - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesEnrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 -Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell Simon, Pharm.D., to the Board of Directors - HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the second quarter ended June 30, 2026, along with key business updates. "We continued on our strategic plan, completing enrollment and dosing in Cohort 1 of the SER-252 registrational stu
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form 10-Q filed by Serina Therapeutics Inc.10-Q - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceHUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will hold virtual one-on-one investor meetings on Wednesday, July 29, 2026. Please contact your BTIG representative to request a meeting. About the POZ Platform™ Serina’s proprietary POZ technology is based on a synthetic, water-soluble, low viscosity polymer called poly(2-oxazoline). The POZ platform is engineered to provide gr
- INSIDERSEC Form 4 filed by Director Simon Farrell4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 3 filed by new insider Simon Farrell3 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol - - Company expects to provide a further update following completion of the Safety Monitoring Committee review – HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of enrollment and dosing in Cohort 1 of its ongoing Phase 1b regist
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics Appoints Farrell Simon to its Board of DirectorsHUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective immediately. Dr. Simon will also serve on the Board's Audit and Compensation Committees. "We are pleased to welcome Dr. Simon to Serina’s Board of Directors," said Steve Ledger, Chief Executive Officer of Serina Therapeutics. "Farrell has been a key leader at Trevi as the company has significantly expanded its enterprise value and raised substantial capital to advance i
- PRSerina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseData Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites in the US and Australia - Company is on track to complete Cohort 1 enrollment and dosing ahead of previously disclosed guidance of the end of the third quarter of 2026 – HUNTSVILLE, Ala., July 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registratio
- INSIDERDirector Brannan Stephen K. bought $2,030 worth of shares (1,000 units at $2.03) (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- ANALYSTBTIG Research initiated coverage on Serina Therapeutics with a new price targetBTIG Research initiated coverage of Serina Therapeutics with a rating of Buy and set a new price target of $8.00
- PRGannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 ProgramHUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE:SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology. Under the agreement, Gannet BioChem will support development activities for SER-252, Serina's investigational therapy for advanced Parkinson's disease. SER-252 recently received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application, enabling the advancement of the program into clinical development. The collaboration brings together Seri
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- INSIDERDirector Venkatesan Jay bought $1,048 worth of shares (589 units at $1.78) and converted options into 224,152 shares (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
SER FAQ
10 questionsWhat is the latest news on SER?
In the last 30 days Quantisnow tracked 1 wire item for SER: 1 13D/G filing. The most recent was published on November 3, 2026.What is SER revenue?
Serina Therapeutics Inc. (SER) reported $0 of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $130.0K.Is SER profitable?
No. Serina Therapeutics Inc. reported a net loss of $21.18M for the twelve months ended Jun 30, 2026.How much cash and debt does SER have?
Serina Therapeutics Inc. reported $23.02M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does SER stock trade?
Serina Therapeutics Inc. (SER) is listed on AMEX.What sector and industry is SER in?
Serina Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Serina Therapeutics Inc. go public?
Serina Therapeutics Inc. (SER) completed its IPO in 2018.What are analysts saying about SER?
Serina Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $8.00 price target on 2026-07-01. Recent price targets range from $8.00 to $15.00.What companies are similar to SER?
Notable peers in the same industry include MRK (Merck & Company Inc.), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare SER side-by-side with any of them on Quantisnow.How can I track SER on Quantisnow?
Quantisnow aggregates Serina Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SER to receive live email and push alerts on every new disclosure.